Human IL-18 Protein, premium grade
分子別名（Synonym）
IL-18,Interleukin-18,IL18,IL-1 gamma,IGIF,IL1F4,IL-1F4
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Human IL-18 Protein, premium grade (IL8-H5114) is expressed from E. coli cells. It contains AA Tyr 37 - Asp 193 (Accession # Q14116-1).
Human IL-18蛋白，premium級(jí)別（IL8-H5114），專為臨床前階段設(shè)計(jì)，具有與GMP級(jí)別IL-18蛋白（GMP-L18H16）相同的活性和性能，可實(shí)現(xiàn)從臨床前開(kāi)發(fā)到臨床階段的無(wú)縫過(guò)渡。在原材料安全不是首要任務(wù)的早期開(kāi)發(fā)階段，premium產(chǎn)品為GMP產(chǎn)品提供了一種經(jīng)濟(jì)高效的替代品。通過(guò)在早期開(kāi)發(fā)階段使用Premium產(chǎn)品，您可以輕松過(guò)渡到臨床和商業(yè)階段，而無(wú)需重新驗(yàn)證原材料和修改制造工藝。
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries no "tag".
The protein has a calculated MW of 18.2 kDa. The protein migrates as 17 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
內(nèi)毒素（Endotoxin）
Less than 0.01 EU per μg by the LAL method.
宿主蛋白殘留（Host Cell Protein）
<0.5 ng/μg of protein tested by ELISA.
宿主核酸殘留（Host Cell DNA）
<0.02 ng/μg of protein tested by qPCR.
無(wú)菌（Sterility）
Negative
支原體（Mycoplasma）
Negative.
純度（Purity）
>95% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
背景（Background）
Interleukin-18 (IL-18) is a potent proinflammatory cytokine that induces interferon-gamma (IFN-gamma) production from Th1 cells, NK cells and activated macrophages, particularly in the presence of IL-12. IL-18 also functions in developmental regulation of T-lymphocyte helper type I cells and in Fas-mediated cytotoxicity. Suppression of IL-18 activity is being investigated for treatment of chronic inflammatory diseases such as Crohn's disease and rheumatoid arthritis. It acts by inducing heterodimerization of the two subunits of its receptor, IL-18RAlpha and IL-18RBeta shows structural similarity to IL-1.
關(guān)鍵字： IL-18;IL-18蛋白;IL-18重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國(guó)生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。